GoldenGolden
KaNDy Therapeutics

KaNDy Therapeutics

KaNDy Therapeutics is a clinical-stage company focused on optimising the potential of NT-814 in the treatment of common, chronic debilitating female sex-hormone related conditions, with an initial focus on symptoms of the menopause.

KaNDy Therapeutics is a clinical-stage company that focuses on optimizing the potential of NT-814 in treating common chronic debilitating female sex-hormone related conditions, with its primary focus on treating several symptoms of the menopause.

KaNDy Therapeutics was a spin-off from NeRRe Therapeutics, which itself is a spin-off from GSK in 2017, and all the data and intellectual properties that were associated with NT-814 were transferred to KaNDy Therapeutics.

KaNDy Therapeutics works under the control of an experienced management team and it is backed by investors who are internationally recognized in life sciences : Fountain Healthcare Partners, Advent Life Sciences, Forbion Capital Partners, OrbiMed and Longitude Capital.

Timeline

August 2018
KaNDy Therapeutics raises a $32,500,000 series C round from Advent Life Sciences, Forbion Capital Partners, Fountain Healthcare Partners, Longitude Capital and OrbiMed.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.